Question 1

How should candidate variants be ranked?

Accepted Answer

By criteria fixed before results are seen, combining predicted binding, evidence of expression in the tumour, and clonality. Ranking chosen after seeing which peptides performed is difficult to defend. Stating the criteria and the weighting, then reporting how the selected set performed against them, is the defensible structure.

Question 2

Does predicted binding indicate immunogenicity?

Accepted Answer

Only weakly. Prediction identifies peptides likely to bind a given allele, but binding is necessary rather than sufficient: presentation, T cell repertoire and tolerance all intervene. Treating prediction as a filter generating candidates, rather than as evidence of a target, keeps the claim proportionate to what was shown.

Question 3

Why does clonality matter for target choice?

Accepted Answer

Because a variant present in only part of the tumour leaves the rest unaffected even if the response is strong. Estimating cancer cell fraction from sequencing and favouring clonal variants improves the odds that a response reaches the whole tumour. Reporting the estimate for each selected variant is worth doing.

Question 4

What does adequate immune monitoring require?

Accepted Answer

Pre-vaccination baseline samples, assays sensitive enough to detect rare antigen-specific cells, and testing against the specific peptides included rather than a general readout. Without a baseline, an apparent response cannot be distinguished from pre-existing reactivity, which is the most common weakness in this evidence.

Question 5

How much does tumour purity affect the pipeline?

Accepted Answer

Considerably. Low purity reduces variant allele fractions and causes real variants to be missed, while normal tissue contamination complicates clonality estimates. Reporting purity for each sample, and acknowledging what it means for detection sensitivity, is more credible than presenting a variant list without that context.

Question 6

Can this work be done without patient samples?

Accepted Answer

Partly. Pipeline development, prediction benchmarking and assay design can proceed on public datasets and cell lines, which suits many doctoral projects. What cannot be established that way is whether selection produces responses in people, so the thesis should be clear about which question the available material answers.

Question 7

What limits the timeline?

Accepted Answer

Manufacturing and regulatory steps, which for an individualised product are substantial and rarely compress. Where a project anticipates reaching patients, scoping approvals and production lead times at the outset prevents a well-designed pipeline from having nowhere to go within the registration period.

Biotechnology

Biotechnology

Research Frontiers in Personalized Cancer Mutanome Vaccines